Hot or Not, Stock Market Edition: 05/26/2026

Happy Tuesday. We looked to the mighty Zen Ratings to see what’s hot and what’s not in the market — here are some of the stories we unearthed:

• Hot: Electrical equipment maker Hubbell (HUBB) quietly benefits from one of the strongest long-term industrial themes in the market; defense contractor Leidos (LDOS) emerges as a strong “picks-and-shovels” play in the defense sector.
• Not: Mortgage lender UWM Holdings (UWMC) is stuck in one of the toughest corners of the market right now; clinical-stage biotech Summit Therapeutics (SMMT) faces rising skepticism

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT: Electrical equipment maker Hubbell (HUBB) is quietly benefiting from one of the strongest long-term industrial themes in the market: America’s power grid upgrade cycle. Utilities, data centers, and manufacturers are all spending aggressively to modernize electrical infrastructure — and Hubbell supplies many of the critical components that make those upgrades possible. That puts the company directly in the path of growing demand tied to AI power consumption, grid resiliency, and infrastructure expansion. Investors are starting to rotate back into high-quality industrial names as interest rates cool, and Hubbell’s recent strength reflects growing confidence that the earnings story still has room to run. Add in a shareholder-friendly dividend and strong institutional ownership, and the setup becomes even more attractive for long-term investors. This idea is supported by the Zen Ratings, where HUBB holds a high-tier Zen Rating (Buy), supported by strong Safety and Financials scores. Bottom line: This is the kind of industrial stock that tends to compound quietly over time — stable business, infrastructure tailwinds, and rising electricity demand all working in its favor at once.

🥶 NOT: Clinical-stage biotech Summit Therapeutics (SMMT) is facing rising skepticism around expectations, and the uncertainty is evident in its roughly 30% dip in the past month or so. Summit became a market favorite on excitement surrounding its oncology pipeline, but recent analyst downgrades suggest Wall Street is starting to question whether the current valuation still makes sense relative to the competitive landscape and remaining execution risk. That shift in sentiment matters in biotech, where stocks are often driven more by future expectations than current fundamentals. Once analysts begin stepping back, momentum can reverse quickly. That could be what’s happening here. On top of that, the company is still a clinical-stage operation with limited financial stability and no fully mature commercial engine to support the valuation if enthusiasm fades. According to WallStreetZen, SMMT carries a D (Sell) rating, weighed down by weak Safety, Financials, and AI scores. The bottom line? Summit may still have promising science — but right now, the stock looks caught between sky-high expectations and growing doubts, which is often a dangerous combination in biotech.

🔥 HOT: Defense contractor Leidos (LDOS) emerging as one of the stronger “picks-and-shovels” plays in the defense sector. The biggest catalyst is the growing wave of federal spending on cybersecurity, AI, defense systems, and infrastructure modernization — all areas where Leidos already has deep government relationships and long-term contracts in place. Unlike pure weapons manufacturers, Leidos benefits from both defense and civilian agency spending, giving it a broader and more stable revenue base as Washington ramps investment in digital infrastructure and national security technology. Investors are increasingly rewarding companies tied to mission-critical government IT services, especially those with dependable cash flows and recurring contracts. According to the Zen Ratings, LDOS earns a B (Buy) Rating, backed by solid individual grades for Financials, Safety, and Momentum. The bottom line? Leidos sits right at the intersection of defense, AI, cybersecurity, and government modernization — four themes that all appear poised to remain major spending priorities for years to come.

🥶 NOT: Mortgage lender UWM Holdings (UWMC) is stuck in one of the toughest corners of the market right now. Elevated interest rates continue crushing refinance activity and pressuring home affordability, which directly limits mortgage origination volume across the industry. Instead of focusing investors on growth, UWMC has become wrapped up in a noisy proxy battle and corporate maneuvering that may generate headlines but hasn’t improved confidence in the actual business. That disconnect is showing up clearly in the stock’s weak momentum and deeply negative sentiment. In the Zen Ratings, UWMC has been downgraded to a (Hold) rating, dragged down by an F in Sentiment and weak scores in Momentum and AI. The bottom line? Until mortgage demand meaningfully recovers and management shifts the narrative back toward operational growth instead of boardroom drama, UWMC looks more like a stagnant yield play than a compelling upside opportunity.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.